WithdrawnPhase 2

Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)

Stopped: Difficulty with recruitment

United States0Started 2011-02

Plain-language summary

The purpose of this study is to determine whether Timolol 0.5% Gel Forming Solution is safe and effective in promoting wound healing of infantile ulcerated hemangiomas compared with standard conservative management with topical antibiotic.

Who can participate

Age range1 Month – 8 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Infants weighing between 4-12kg * Infants with corrected gestational age 44 weeks - 8 months of age * Infant with an ulcerated hemangioma * Informed consent Exclusion Criteria: * Ulceration larger than 16cm2 * Ulcerated hemangioma with active bleeding or infection at time of enrollment * Disease threatening hemangioma meeting criteria for oral propranolol * Previous treatment with topical/oral corticosteroid or propranolol * Medical history of congenital heart disease with decreased cardiac output, stroke/cerebral vasculopathy, active reactive airway disease or metabolic disorder * History of an allergic reaction to Mupirocin or Timolol * Currently taking medication that would interact with beta-blockers

What they're measuring

Time to Wound Re-epithelization

Timeframe: At 3 months

Trial details

NCT IDNCT01408056

SponsorChildren's Hospital of Philadelphia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-01

View on ClinicalTrials.gov More Infantile Hemangiomas trials